Drugs / ieramilimab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03742349 | Jan 2019 → Feb 2023 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02460224 | Jun 2015 → Dec 2020 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03484923 | Sep 2018 → Dec 2022 | melanoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03499899 | Jul 2018 → Feb 2020 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03365791 | Jan 2018 → Feb 2019 | diffuse large B-cell lymphoma, esophageal adenocarcinoma, gastric adenocarcinoma, ovarian adenocarcinoma +3 | Novartis Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-03-18 | Immutep S.A.S. | Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525 immutep.com ↗ |
| 2021-08-26 | Immutep S.A.S. | Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525 immutep.com ↗ |
| 2021-04-06 | Immutep S.A.S. | Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy immutep.com ↗ |
| 2019-11-13 | Immutep S.A.S. | Immutep Announces European Patent Grant for LAG525 Antibody immutep.com ↗ |
| 2019-09-16 | Immutep S.A.S. | Immutep Announces Japanese Patent Grant for LAG525 Antibody immutep.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ieramilimab | “Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.” PMID 35217575 ↗ Feb 2022 |
| Known as | Humanised imp-701 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298009 ↗ |
| Known as | LAG525 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02460224 ↗ |
| Known as | NVP-LAG525 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298009 ↗ |
| Action | Inhibit | “LAG-3 inhibitor ieramilimab (LAG525)” PMID 35217575 ↗ Feb 2022 |
| Modality | Monoclonal antibody | “humanized anti-LAG-3 IgG4 antibody” NCT03365791 ↗ |
| Route | Intravenous | “LAG525 was administered via intravenous (i.v.) infusion” NCT02460224 ↗ |
| Target | LAG3 | “tumor target (LAG-3) suppression with 600 mg ieramilimab Q4W was predicted to be similar to the Q4W, RP2D schedule.” PMID 35217575 ↗ Feb 2022 |